Verapamil
Tarka, Verelan (verapamil) is a small molecule pharmaceutical. Verapamil was first approved as Isoptin on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1S and voltage-dependent L-type calcium channel subunit alpha-1C. In addition, it is known to target potassium voltage-gated channel subfamily A member 7, sodium leak channel NALCN, two pore channel protein 2, two pore channel protein 1, equilibrative nucleoside transporter 4, voltage-dependent L-type calcium channel subunit alpha-1D, cytochrome P450 3A4, potassium voltage-gated channel subfamily A member 10, potassium voltage-gated channel subfamily C member 2, voltage-dependent L-type calcium channel subunit alpha-1F, and G protein-activated inward rectifier potassium channel 2.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Verelan (generic drugs available since 1986-10-01, discontinued: Calan, Covera, Isoptin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trandolapril
+
Verapamil hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TARKA | AbbVie | N-020591 DISCN | 1996-10-22 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| calan sr | New Drug Application | 2023-06-20 |
| isoptin sr | 2008-03-11 | |
| it cosmetics your skin but better cc plus nude glow color correcting medium coverage skin tint brightening glow serum broad spectrum spf 40 sunscre... | OTC monograph not final | 2023-04-25 |
| tarka | New Drug Application | 2012-02-13 |
| verelan | New Drug Application | 2023-02-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
| atrial flutter | EFO_0003911 | D001282 | — |
| hypertension | EFO_0000537 | D006973 | I10 |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| supraventricular tachycardia | HP_0004755 | D013617 | I47.1 |
| variant angina pectoris | — | D000788 | I20.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08D: Selective calcium channel blockers with direct cardiac effects
— C08DA: Phenylalkylamine derivatives, selective calcium channel blockers with direct cardiac effects
— C08DA01: Verapamil
— C08DA51: Verapamil, combinations
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB10: Trandolapril and verapamil
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 5 | — | 6 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | 2 | 1 | 1 | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | 1 | — | 2 |
| Percutaneous coronary intervention | D062645 | — | — | — | 1 | 1 | 2 | ||
| Ventricular tachycardia | D017180 | I47.2 | — | 1 | 1 | 1 | — | 2 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 2 | — | 2 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | — | — | 2 |
| Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | — | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | — | 1 |
| Mania | D000087122 | F30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 18 | 1 | — | — | — | 18 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | — | 1 | 3 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | 1 | — | — | — | 1 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | 4 | — | — | — | — | 4 | ||
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | — | — | — | 1 | 2 |
| Nasal polyps | D009298 | HP_0100582 | J33 | 1 | — | — | — | 1 | 2 |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 | |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | 1 | — | — | — | — | 1 | |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | — | — | — | — | 1 | |
| Heart rate | D006339 | EFO_0004326 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic constriction | D003251 | — | — | — | — | 2 | 2 | ||
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | 1 | 1 | ||
| No-reflow phenomenon | D054318 | — | — | — | — | 1 | 1 | ||
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Supraventricular tachycardia | D013617 | HP_0004755 | I47.1 | — | — | — | — | 1 | 1 |
| Ventricular premature complexes | D018879 | I49.3 | — | — | — | — | 1 | 1 | |
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Seizures | D012640 | G40.4 | — | — | — | — | 1 | 1 | |
| Arteriovenous fistula | D001164 | Q27.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VERAPAMIL |
| INN | verapamil |
| Description | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile. |
| Classification | Small molecule |
| Drug class | coronary vasodilators (verapamil type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 52-53-9 |
| RxCUI | 11170 |
| ChEMBL ID | CHEMBL6966 |
| ChEBI ID | 77733 |
| PubChem CID | 2520 |
| DrugBank | DB00661 |
| UNII ID | CJ0O37KU29 (ChemIDplus, GSRS) |
Target
Agency Approved
CACNA1S
CACNA1S
CACNA1C
CACNA1C
Organism
Homo sapiens
Gene name
CACNA1S
Gene synonyms
CACH1, CACN1, CACNL1A3
NCBI Gene ID
Protein name
voltage-dependent L-type calcium channel subunit alpha-1S
Protein synonyms
Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle, calcium channel, voltage-dependent, L type, alpha 1S subunit, dihydropyridine receptor alpha 1 subunit, dihydropyridine-sensitive L-type calcium channel alpha-1 subunit, Voltage-gated calcium channel subunit alpha Cav1.1
Uniprot ID
Mouse ortholog
Cacna1s (12292)
voltage-dependent L-type calcium channel subunit alpha-1S (Q99240)
Alternate
KCNA7
KCNA7
NALCN
NALCN
TPCN2
TPCN2
TPCN1
TPCN1
SLC29A4
SLC29A4
CACNA1D
CACNA1D
CYP3A4
CYP3A4
KCNA10
KCNA10
KCNC2
KCNC2
CACNA1F
CACNA1F
KCNJ6
KCNJ6
Organism
Homo sapiens
Gene name
KCNA7
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily A member 7
Protein synonyms
potassium channel, voltage gated shaker related subfamily A, member 7, potassium voltage-gated channel, shaker-related subfamily, member 7, voltage-dependent potassium channel Kv1.7, voltage-gated potassium channel KCNA7, Voltage-gated potassium channel subunit Kv1.7
Uniprot ID
Mouse ortholog
Kcna7 (16495)
potassium voltage-gated channel subfamily A member 7 (Q17ST2)
Variants
Clinical Variant
No data
Financial
Verelan - Elan Corporation
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 29,903 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tarka
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,353 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more